{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:59:03Z","timestamp":1790614743295,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Regulators are increasingly concerned with \u00a0the\u00a0impact of recalls on drug adherence. In 2018, N-nitrosamines impurities were\u00a0detected in valsartan containing medical products. Concerned\u00a0products were immediately recalled in July 2018 by regulatory agencies internationally. In Germany, recalls were issued for valsartan, losartan and irbesartan from July 2018 to March 2019. This study examined angiotensin II receptor blocker (ARB) utilization trends and switching patterns in Germany before and after July 2018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients prescribed ARBs from January 2014 to June 2020 in general practices in Germany were included in a collaborative framework common protocol drug utilization study led by the US Food and Drug Administration. Trends in monthly and quarterly proportions of total ARB prescribing were analysed for individual ARBs using descriptive statistics and interrupted time series analysis. The rate of switching to an alternative ARB was analysed before and after the recalls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The proportion of valsartan prescriptions immediately decreased from 35.9 to 17.8% following the first recalls in July 2018, mirrored by an increased proportion for candesartan. Increased switching from valsartan to candesartan was observed. No increased switching was observed after losartan recalls, whereas for irbesartan, increased switching was observed 6\u201312\u00a0months after the last recall. Increased switching from ARBs to angiotensin-converting enzyme (ACE) inhibitors or ARB treatment discontinuations were not observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study showed that patients were able to continue ARB treatment despite the July 2018\u2013March 2019 recalls, although many patients needed to switch to an alternative ARB. The duration of the impact of ARB recalls appeared to be limited.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-022-03439-3","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T16:02:47Z","timestamp":1682352167000},"page":"849-858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization\u00a0\u2013\u00a0results from IQVIA\u2122 Disease Analyzer Germany"],"prefix":"10.1007","volume":"79","author":[{"given":"Karin","family":"Hedenmalm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Quinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efe","family":"Eworuke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"key":"3439_CR1","unstructured":"European Medicines Agency (2018) EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. In: ed"},{"issue":"18","key":"3439_CR2","doi-asserted-by":"publisher","first-page":"9465","DOI":"10.3390\/ijerph18189465","volume":"18","author":"K Li","year":"2021","unstructured":"Li K, Ricker K, Tsai FC, Hsieh CJ, Osborne G, Sun M, Marder ME, Elmore S, Schmitz R, Sandy MS (2021) Estimated cancer risks associated with nitrosamine contamination in commonly used medications. Int J Environ Res Public Health 18(18):9465","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"3439_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/oem.57.3.180","volume":"57","author":"K Straif","year":"2000","unstructured":"Straif K, Weiland SK, Bungers M, Holthenrich D, Taeger D, Yi S, Keil U (2000) Exposure to high concentrations of nitrosamines and cancer mortality among a cohort of rubber workers. Occup Environ Med 57(3):180\u2013187. https:\/\/doi.org\/10.1136\/oem.57.3.180","journal-title":"Occup Environ Med"},{"key":"3439_CR4","unstructured":"European Medicines Agency (2020) Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on\u00a0 nitrosamine impurities in human medicinal products. In: ed. European Medicines Agency"},{"issue":"5944","key":"3439_CR5","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/306638a0","volume":"306","author":"VM Craddock","year":"1983","unstructured":"Craddock VM (1983) Nitrosamines and human cancer: proof of an association? Nature 306(5944):638. https:\/\/doi.org\/10.1038\/306638a0","journal-title":"Nature"},{"key":"3439_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13027-018-0174-9","volume":"13","author":"M Cascella","year":"2018","unstructured":"Cascella M, Bimonte S, Barbieri A, Del Vecchio V, Caliendo D, Schiavone V, Fusco R, Granata V, Arra C, Cuomo A (2018) Dissecting the mechanisms and molecules underlying the potential carcinogenicity of red and processed meat in colorectal cancer (CRC): an overview on the current state of knowledge. Infect Agent Cancer 13:3. https:\/\/doi.org\/10.1186\/s13027-018-0174-9","journal-title":"Infect Agent Cancer"},{"key":"3439_CR7","unstructured":"Food and Drug Administration (2018) FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. In: ed"},{"key":"3439_CR8","doi-asserted-by":"publisher","DOI":"10.21542\/gcsp.2020.25","volume":"2","author":"A Ray","year":"2020","unstructured":"Ray A, Atal S (2020) Sadasivam B (2020) Understanding the molecular-pharmaceutical basis of sartan recalls focusing on valsartan. Global cardiology science & practice 2:e202025. https:\/\/doi.org\/10.21542\/gcsp.2020.25","journal-title":"Global cardiology science & practice"},{"key":"3439_CR9","unstructured":"German Federal Institute for Drugs and Medical Devices (2018) Valsartan: chargenbezogener R\u00fcckruf valsartanhaltiger Arzneimittel, deren Wirkstoff von dem chinesischen Hersteller Zhejiang Huahai Pharmaceutical produziert wurde. In: ed. BfArM"},{"key":"3439_CR10","unstructured":"Arzneimittelkommission der Deutschen Apotheker (2019) Online-Nachricht: AMK: Liste der (Chargen-)R\u00fcckrufe Sartan-haltiger Arzneimittel. In: ed. Bundesvereinigung Deutscher Apothekerverb\u00e4nde e.V"},{"issue":"10","key":"3439_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5414\/CPP47617","volume":"47","author":"H Becher","year":"2009","unstructured":"Becher H, Kostev K, Schroder-Bernhardi D (2009) Validity and representativeness of the \u201cDisease Analyzer\u201d patient database for use in pharmacoepidemiological and pharmacoeconomic studies. Int J Clin Pharmacol Ther 47(10):617\u2013626","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"3439_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.5414\/cp203320","volume":"56","author":"W Rathmann","year":"2018","unstructured":"Rathmann W, Bongaerts B, Carius HJ, Kruppert S, Kostev K (2018) Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther 56(10):459\u2013466. https:\/\/doi.org\/10.5414\/cp203320","journal-title":"Int J Clin Pharmacol Ther"},{"key":"3439_CR13","unstructured":"World Health Organisation (2018) Definition and general considerations. In: ed. WHO Collaborating Centre for Drug Statistics Methodology"},{"issue":"4","key":"3439_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27(4):299\u2013309. https:\/\/doi.org\/10.1046\/j.1365-2710.2002.00430.x","journal-title":"J Clin Pharm Ther"},{"key":"3439_CR15","unstructured":"Dean AG, Sullivan KM, Soe MM. Compare two rates. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com. Updated 6 April\u00a02013. Accessed 17 Feb 2023"},{"issue":"5","key":"3439_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/00001648-199109000-00008","volume":"2","author":"D Martin","year":"1991","unstructured":"Martin D, Austin H (1991) An efficient program for computing conditional maximum likelihood estimates and exact confidence limits for a common odds ratio. Epidemiology 2(5):359\u2013362. https:\/\/doi.org\/10.1097\/00001648-199109000-00008","journal-title":"Epidemiology"},{"issue":"1","key":"3439_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00001648-199601000-00006","volume":"7","author":"DO Martin","year":"1996","unstructured":"Martin DO, Austin H (1996) Exact estimates for a rate ratio. Epidemiology 7(1):29\u201333. https:\/\/doi.org\/10.1097\/00001648-199601000-00006","journal-title":"Epidemiology"},{"issue":"1","key":"3439_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A (2017) Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol 46(1):348\u2013355. https:\/\/doi.org\/10.1093\/ije\/dyw098","journal-title":"Int J Epidemiol"},{"key":"3439_CR19","unstructured":"Prescrire (2016) Hypertension: avoid olmesartan pending its withdrawal. In: ed. Prescrire Int"},{"issue":"10","key":"3439_CR20","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/gutjnl-2015-309690","volume":"65","author":"M Basson","year":"2016","unstructured":"Basson M, Mezzarobba M, Weill A, Ricordeau P, Allemand H, Alla F, Carbonnel F (2016) Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. Gut 65(10):1664\u20131669. https:\/\/doi.org\/10.1136\/gutjnl-2015-309690","journal-title":"Gut"},{"issue":"3","key":"3439_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/ehjcvp\/pvz037","volume":"6","author":"J Tamargo","year":"2020","unstructured":"Tamargo J, Rosano G (2020) Low quality of some generic cardiovascular medicinal products represents a matter for growing concern. Eur Heart J Cardiovasc Pharmacother 6(3):176\u2013187. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz037","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"3439_CR22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40262-020-00909-8","volume":"59","author":"PJ Glerum","year":"2020","unstructured":"Glerum PJ, Neef C, Burger DM, Yu Y, Maliepaard M (2020) Pharmacokinetics and generic drug switching: a regulator\u2019s view. Clin Pharmacokinet 59(9):1065\u20131069. https:\/\/doi.org\/10.1007\/s40262-020-00909-8","journal-title":"Clin Pharmacokinet"},{"key":"3439_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.yrtph.2019.01.007","volume":"103","author":"DJ Snodin","year":"2019","unstructured":"Snodin DJ, Elder DP (2019) Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products. Regul Toxicol Pharmacol 103:325\u2013329. https:\/\/doi.org\/10.1016\/j.yrtph.2019.01.007","journal-title":"Regul Toxicol Pharmacol"},{"issue":"9","key":"3439_CR24","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","volume":"110","author":"B Tuesuwan","year":"2021","unstructured":"Tuesuwan B, Vongsutilers V (2021) Nitrosamine contamination in pharmaceuticals: threat, impact, and control. J Pharm Sci 110(9):3118\u20133128. https:\/\/doi.org\/10.1016\/j.xphs.2021.04.021","journal-title":"J Pharm Sci"},{"key":"3439_CR25","unstructured":"European Medicines Agency (2021) Nitrosamine impurities. In: ed. European Medicines Agency"},{"key":"3439_CR26","unstructured":"European Medicines Agency (2020) Ranitidine-containing products. EMA confirms recommendation to suspend all ranitidine medicines in the EU. In: ed. European Medicines Agency"},{"key":"3439_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3851","volume":"362","author":"A Potteg\u00e5rd","year":"2018","unstructured":"Potteg\u00e5rd A, Kristensen KB, Ernst MT, Johansen NB, Quartarolo P, Hallas J (2018) Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. BMJ (Clinical research ed) 362:k3851. https:\/\/doi.org\/10.1136\/bmj.k3851","journal-title":"BMJ (Clinical research ed)"},{"issue":"1","key":"3439_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1055-9965.epi-21-0737","volume":"31","author":"M N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard M, Andersen IT, Heide-J\u00f8rgensen U, Erichsen R, Rees JR, Karagas MR, S\u00f8rensen HT (2022) Ranitidine and risk of bladder and kidney cancer: a population-based cohort study. Cancer epidemiology, biomarkers & prevention\u202f: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 31(1):45\u201350. https:\/\/doi.org\/10.1158\/1055-9965.epi-21-0737","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"12","key":"3439_CR29","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1158\/1055-9965.epi-21-0831","volume":"30","author":"HO Adami","year":"2021","unstructured":"Adami HO, Trolle Andersen I, Heide-J\u00f8rgensen U, Chang ET, N\u00f8rgaard M, S\u00f8rensen HT (2021) Ranitidine use and risk of upper gastrointestinal cancers. Cancer epidemiology, biomarkers & prevention\u202f: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 30(12):2302\u20132308. https:\/\/doi.org\/10.1158\/1055-9965.epi-21-0831","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"issue":"5","key":"3439_CR30","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1053\/j.gastro.2020.12.037","volume":"160","author":"ED Kantor","year":"2021","unstructured":"Kantor ED, O\u2019Connell K, Du M, Mendelsohn RB, Liang PS, Braunstein LZ (2021) Ranitidine use and cancer risk: results from UK Biobank. Gastroenterology 160(5):1856-1859.e1855. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.037","journal-title":"Gastroenterology"},{"issue":"8","key":"3439_CR31","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.14309\/ajg.0000000000001310","volume":"116","author":"CR Cardwell","year":"2021","unstructured":"Cardwell CR, McDowell RD, Hughes CM, Hicks B, Murchie P (2021) Exposure to ranitidine and risk of bladder cancer: a nested case-control study. Am J Gastroenterol 116(8):1612\u20131619. https:\/\/doi.org\/10.14309\/ajg.0000000000001310","journal-title":"Am J Gastroenterol"},{"issue":"21","key":"3439_CR32","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3238\/arztebl.m2021.0129","volume":"118","author":"W Gomm","year":"2021","unstructured":"Gomm W, R\u00f6thlein C, Sch\u00fcssel K, Br\u00fcckner G, Schr\u00f6der H, He\u00df S, Fr\u00f6tschl R, Broich K, Haenisch B (2021) N-nitrosodimethylamine-contaminated valsartan and the risk of cancer\u2014a longitudinal cohort study based on German Health Insurance Data. Dtsch Arztebl Int 118(21):357\u2013362. https:\/\/doi.org\/10.3238\/arztebl.m2021.0129","journal-title":"Dtsch Arztebl Int"},{"issue":"5","key":"3439_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/em.22434","volume":"62","author":"BP Engelward","year":"2021","unstructured":"Engelward BP (2021) Implications of an epidemiological study showing an association between in utero NDMA exposure and childhood cancer. Environ Mol Mutagen 62(5):288\u2013292. https:\/\/doi.org\/10.1002\/em.22434","journal-title":"Environ Mol Mutagen"},{"key":"3439_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00425-z","author":"UM Rudolph","year":"2020","unstructured":"Rudolph UM, Enners S, Kieble M, Mahfoud F, B\u00f6hm M, Laufs U, Schulz M (2020) Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. J Hum Hypertens. https:\/\/doi.org\/10.1038\/s41371-020-00425-z","journal-title":"J Hum Hypertens"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03439-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03439-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03439-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T08:15:27Z","timestamp":1685434527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03439-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["3439"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03439-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The IQVIA\u2122 Disease Analyzer Germany database contains deanonymized patient data and no ethical approval was required for use of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency\/agencies or organisations with which the author(s) is\/are employed\/affiliated.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}